Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : Alvogen
Deal Size : $345.0 million
Deal Type : Collaboration
NRx Pharmaceuticals Announces $5 Million Milestone from Alvogen and Lotus Pharma
Details : The collaborations aim to support NRx for the development of NRX-101 (D-cycloserine) in the treatment of bipolar depression with suicidality.
Product Name : NRX-101
Product Type : Other Small Molecule
Upfront Cash : $10.0 million
November 02, 2024
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : Alvogen
Deal Size : $345.0 million
Deal Type : Collaboration
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NRx Reports Trial Results Showing Safety of NRX-101 in Suicidal Bipolar Depression
Details : NRX-101 (D-cycloserine & Lurasidone HCl) is a fixed dose combination which is under clinical development for various indications including for the treatment of suicidal bipolar depression.
Product Name : NRX-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 05, 2024
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NRx Announces Promising Findings in Phase 2b/3 of NRX-101 for Suicidal Bipolar Depression
Details : NRX-101 (D-cycloserine & Lurasidone HCl) is a fixed dose combination which is under clinical development for various indications including for the treatment of suicidal bipolar depression.
Product Name : NRX-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 30, 2024
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NRx Reports NRX-101 Shows No Damage To Intestinal Flora
Details : NRX-101 (D-cycloserine & Lurasidone HCl) shows no measurable damage to intestinal or vaginal flora in rodent models of urinary tract infections and associated complications.
Product Name : NRX-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 17, 2024
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NRx Pharmaceuticals Announces Last Patient, Last Visit in Phase 2b/3 Trial Of NRX-101
Details : NRX-101, a combination of the NMDA antagonist D-cycloserine and lurasidone, is in phase 2/3 trials for treating resistant bipolar depression and suicidal ideation.
Product Name : NRX-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 03, 2024
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NRx Pharmaceuticals Completes Enrollment Of Phase 2b/3 Trial Of NRX-101
Details : NRX-101, a fixed-dose combination of D-cycloserine and lurasidone, is in phase 2/3 trials for treatment-resistant bipolar depression and suicidal ideation.
Product Name : NRX-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2024
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NRx Pharmaceuticals Announces FDA QIDP and Fast Track Designation for NRX-101
Details : NRX-101 combines D-cycloserine and lurasidone, currently in Phase 2 for treating complicated urinary tract infections and pyelonephritis.
Product Name : NRX-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NRX-101 is an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain's N-methyl-D-aspartate (NMDA) receptor. It is being evaluated for the treatment of complicated Urinary Tract Infections.
Product Name : NRX-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2023
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain's N-methyl-D-aspartate (NMDA) receptor and is being investigated for Chronic Pain.
Product Name : NRX-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lurasidone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurobindo's Generic Lurasidone Hydrochloride Receives Approval in U.S.
Details : Lurasidone hydrochloride is an atypical antipsychotic that is a D2 and 5-HT2A (mixed serotonin and dopamine activity) to improve cognition. It improves negative symptoms of psychoses and reduce the extrapyramidal side effects associated with typical anti...
Product Name : Lurasidone Hydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2023
Lead Product(s) : Lurasidone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable